Results from a recently published study in Menopause indicate that higher endogenous estrogen exposure (EEE) and hormone therapy (HT) may lead to better cognition for women in later life.
©Rido - stock.adobe.com
Results from a recent study appearing in Menopause indicate that higher endogenous estrogen exposure (EEE) and hormone therapy (HT) may lead to higher cognitive status for women in later life. The results are based on a 12-year population study that included over 2000 adult women.
Methods
The study used data from the Cache County Study on Memory in Aging - a population based-sample of over 5,092 residents (2,928 women) living in Cache County, Utah. The study relied on four triennial waves of dementia ascertainment over the course of 12 years to identify factors for Alzheimer’s Disease. Because Alzheimer’s disease is more prevalent in women, and possibly influenced by sex-dependent effects of estrogen, this study explored the effect of lifetime estrogen exposure on late-life cognitive decline. Lifetime estrogen exposure was based on endogenous exposure (time of menarche to menopause), number of pregnancies, duration of breast feeding and HT use.
The baseline sample for this study included 2,114 women (mean age=74.94 years, standard deviation [SD] =6.7) who were dementia-free at baseline and completed an adaption of the 100-point modified Mini-Mental State Examination (3MS) questionnaire. The questionnaire focused on the participant’s reproductive history and HT use. EEE was calculated by taking the reproductive window (age at menarche to age at menopause) and was adjusted for pregnancy and breastfeeding. Relevant HT variables included duration of use, HT type (unopposed vs opposed), and time HT initiation. The authors used linear mixed-effects models to examine the relationship between estrogen exposure and 3MS scores over time.
Results
The authors found that:
Conclusion
The authors believe their findings indicate that longer EEE and HT use, especially in older women are associated with higher cognitive status later in life. Future research might investigate factors known to disrupt endogenous estrogen, such as cancer, or focus on the initiation of HT in late-life in order to compare health-related factors between participants to help clarify the effects of HT on late-life cognition.
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Study reveals critical gaps in care for PCOS patients
May 17th 2024A new study presented at the 2024 ACOG Annual Clinical and Scientific Meeting highlighted significant gaps in polycystic ovary syndrome (PCOS) care, revealing widespread patient dissatisfaction and the urgent need for improved provider education and comprehensive treatment approaches.
Read More
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.
Read More